Clinical Trial

Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-05.
Trial Details
NCT Number NCT06869174
Lead Sponsor Zhiguo Luo, MD, PhD
Conditions Cancer of Unknown Primary
Enrollment 50 participants
Start Date 2025-03-08
Primary Completion 2027-03-08 (estimated)
Study Completion 2028-08-08 (estimated)
Updated on ClinicalTrials.gov 2025-03-12